165 related articles for article (PubMed ID: 28835741)
21. Treatment preferences in relation to fatigue of patients with relapsing multiple sclerosis: A discrete choice experiment.
Tervonen T; Fox RJ; Brooks A; Sidorenko T; Boyanova N; Levitan B; Hennessy B; Phillips-Beyer A
Mult Scler J Exp Transl Clin; 2023; 9(1):20552173221150370. PubMed ID: 36714174
[TBL] [Abstract][Full Text] [Related]
22. A discrete choice experiment to determine patient preferences for injection devices in multiple sclerosis.
Shingler SL; Swinburn P; Ali S; Perard R; Lloyd AJ
J Med Econ; 2013 Aug; 16(8):1036-42. PubMed ID: 23730944
[TBL] [Abstract][Full Text] [Related]
23. Rituximab for relapsing-remitting multiple sclerosis.
He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
[TBL] [Abstract][Full Text] [Related]
24. Comparing preferences for outcomes of psoriasis treatments among patients and dermatologists in the U.K.: results from a discrete-choice experiment.
Gonzalez JM; Johnson FR; McAteer H; Posner J; Mughal F
Br J Dermatol; 2017 Mar; 176(3):777-785. PubMed ID: 27292093
[TBL] [Abstract][Full Text] [Related]
25. Patient Preferences for Treating "OFF" Episodes in Parkinson's Disease: A Discrete Choice Experiment.
Thach A; Sutphin J; Coulter J; Leach C; Pappert E; Mansfield C
Patient Prefer Adherence; 2021; 15():1187-1196. PubMed ID: 34103902
[TBL] [Abstract][Full Text] [Related]
26. Patient Preferences for Unresectable Hepatocellular Carcinoma Treatments: A Discrete-Choice Experiment.
Li D; Tan R; Hernandez S; Reilly N; Bussberg C; Mansfield C
Cancers (Basel); 2023 Feb; 15(5):. PubMed ID: 36900262
[TBL] [Abstract][Full Text] [Related]
27. Patient preferences for diabetes treatment attributes and drug classes.
Flood EM; Bell KF; de la Cruz MC; Ginchereau-Sowell FM
Curr Med Res Opin; 2017 Feb; 33(2):261-268. PubMed ID: 27779433
[TBL] [Abstract][Full Text] [Related]
28. Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis.
Wilson LS; Loucks A; Gipson G; Zhong L; Bui C; Miller E; Owen M; Pelletier D; Goodin D; Waubant E; McCulloch CE
Int J MS Care; 2015; 17(2):74-82. PubMed ID: 25892977
[TBL] [Abstract][Full Text] [Related]
29. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
Fifer S; Rose J; Hamrosi KK; Swain D
BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
[TBL] [Abstract][Full Text] [Related]
30. Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment.
González JM; Ogale S; Morlock R; Posner J; Hauber B; Sommer N; Grothey A
Cancer Manag Res; 2017; 9():149-158. PubMed ID: 28490902
[TBL] [Abstract][Full Text] [Related]
31. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
32. Patient and caregiver preferences for haemophilia treatments: A discrete-choice experiment.
Garcia VC; Mansfield C; Pierce A; Leach C; Smith JC; Afonso M
Haemophilia; 2024 Mar; 30(2):375-387. PubMed ID: 38198352
[TBL] [Abstract][Full Text] [Related]
33. Physician and patient benefit-risk preferences from two randomized long-acting injectable antipsychotic trials.
Katz EG; Hauber B; Gopal S; Fairchild A; Pugh A; Weinstein RB; Levitan BS
Patient Prefer Adherence; 2016; 10():2127-2139. PubMed ID: 27799749
[TBL] [Abstract][Full Text] [Related]
34. Patient, Caregiver, and Nurse Preferences for Treatments for Bone Metastases from Solid Tumors.
Qian Y; Arellano J; Hauber AB; Mohamed AF; Gonzalez JM; Hechmati G; Gatta F; Harrelson S; Campbell-Baird C
Patient; 2016 Aug; 9(4):323-33. PubMed ID: 26821359
[TBL] [Abstract][Full Text] [Related]
35. Treatment preferences among Japanese women with dysmenorrhea: results from a discrete choice experiment study.
Akiyama S; Goren A; Basurto E; Komori T; Harada T
Patient Prefer Adherence; 2018; 12():1627-1640. PubMed ID: 30214165
[TBL] [Abstract][Full Text] [Related]
36. A survey of patient preferences for oral antihyperglycemic therapy in patients with type 2 diabetes mellitus.
Hauber AB; Tunceli K; Yang JC; Gantz I; Brodovicz KG; Alexander CM; Davies MJ; Radican L
Diabetes Ther; 2015 Mar; 6(1):75-84. PubMed ID: 25586555
[TBL] [Abstract][Full Text] [Related]
37. Quantitative analysis of multiple sclerosis patients' preferences for drug treatment: a best-worst scaling study.
Lynd LD; Traboulsee A; Marra CA; Mittmann N; Evans C; Li KH; Carter M; Hategekimana C
Ther Adv Neurol Disord; 2016 Jul; 9(4):287-96. PubMed ID: 27366235
[TBL] [Abstract][Full Text] [Related]
38. Patient preferences for treatment in type 2 diabetes: the Italian discrete-choice experiment analysis.
Marchesini G; Pasqualetti P; Anichini R; Caputo S; Memoli G; Ponzani P; Resi V; Rizzo M; Serviddio G; Zanette G
Acta Diabetol; 2019 Mar; 56(3):289-299. PubMed ID: 30306406
[TBL] [Abstract][Full Text] [Related]
39. The Effect of Disease Modifying Therapies on Disease Progression in Patients with Relapsing-Remitting Multiple Sclerosis: A Systematic Review and Meta-Analysis.
Tsivgoulis G; Katsanos AH; Grigoriadis N; Hadjigeorgiou GM; Heliopoulos I; Papathanasopoulos P; Kilidireas C; Voumvourakis K; Dardiotis E;
PLoS One; 2015; 10(12):e0144538. PubMed ID: 26642051
[TBL] [Abstract][Full Text] [Related]
40. Physicians' preferences for bone metastases drug therapy in the United States.
Arellano J; Hauber AB; Mohamed AF; Gonzalez JM; Collins H; Hechmati G; Gatta F; Qian Y
Value Health; 2015 Jan; 18(1):78-83. PubMed ID: 25595237
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
